Brain Advance Access originally published online on July 7, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 8, 1748-1754,
August 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh195
CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3–/– mice and in Batten disease
1 Department of Pathology and Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, USA and 2 Department of Paediatrics and Child Health, Royal Free and University College Medical School, London, UK
Correspondence to: Michael J. Bennett, Department of Pathology and Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA E-mail: michaelj.bennett{at}utsouthwestern.edu
Batten disease is a severe autosomal recessive neurodegenerative disease which results from mutations in CLN3. Although the gene was cloned in 1995, the tissue distribution and subcellular localization of the CLN3 protein (CLN3P) remains inconclusive. We have demonstrated the presence of a novel 33 kDa protein in both normal human and wild-type mouse brain. This 33 kDa protein, which is overexpressed in brains of patients with Batten disease and in Cln3–/– mouse brain, binds to the antibody raised against the peptide sequence of CLN3P and results in aberrant CLN3P localization studies. We expressed a novel 33 kDa protein that is highly similar to CLN3P. We showed that the 33 kDa protein is identical to that recognized in Batten disease and Cln3–/– brain. These studies strongly suggest the presence of an alternative CLN3-like (CLN3L) product in Batten disease. Previous studies of CLN3P tissue distribution and intracellular localization will require extensive reanalysis in order to determine the true expression of CLN3P.